Advertisement
Parathyroid| Volume 171, ISSUE 1, P40-46, January 2022

Recurrence after successful parathyroidectomy—Who should we worry about?

Published:August 02, 2021DOI:https://doi.org/10.1016/j.surg.2021.06.035

      Abstract

      Background

      Preventing cervical reoperations is important—especially after parathyroidectomy. We sought to examine early predictors of recurrence of primary hyperparathyroidism after surgical cure.

      Methods

      Adult patients with sporadic primary hyperparathyroidism treated with parathyroidectomy between September 1, 1997, and September 1, 2019, with confirmed eucalcemia at 6 months postoperatively were identified. Recurrence was defined as hypercalcemia (>10.2 mg/dL) with an elevated or nonsuppressed parathyroid hormone level on subsequent follow-up.

      Results

      Parathyroidectomy was performed in 522 patients (median age, 62.1 years, 77% female) with the majority undergoing planned minimally invasive parathyroidectomy (85.4%, n = 446). After a median follow-up of 30.9 months, 13 patients (2.5%) recurred (median time to recurrence 50.2 months, interquartile range 27.9–66.5), all of whom underwent planned minimally invasive parathyroidectomy (n = 13/446, 2.9%). Recurrence was more common in those with higher (but still normal) 6-month calcium (10.1 vs 9.3 mg/dL, P < .001) or parathyroid hormone values (64 vs 46 pg/mL, P < .01). Multivariate analysis revealed that age >66.5 years, calcium ≥9.8mg/dL and parathyroid hormone ≥80 pg/mL at 6 months were associated with increased risk of recurrence. In addition, the presence of at least 1 preoperative imaging study that conflicted with intraoperative findings among minimally invasive parathyroidectomy patients (n = 446) was associated with increased risk of recurrence (hazard ratio 4.93, 95% confidence interval 1.25–16.53, P = .016).

      Conclusion

      Recurrence of sporadic primary hyperparathyroidism after initial surgical cure in the era of minimally invasive parathyroidectomy is 2.5%. Identification of those at risk for recurrence using 6-month serum calcium ≥9.8 mg/dL, parathyroid hormone ≥80 pg/mL, and/or potentially conflicting localization studies may inform surveillance strategies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adler J.T.
        • Sippel R.S.
        • Chen H.
        New trends in parathyroid surgery.
        Curr Probl Surg. 2010; 47: 958-1017
        • Press D.M.
        • Siperstein A.E.
        • Berber E.
        • et al.
        The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: A population-based analysis from the electronic medical record.
        Surgery. 2013; 154 (discussion 1237–1238): 1232-1237
        • Yeh M.W.
        • Ituarte P.H.
        • Zhou H.C.
        • et al.
        Incidence and prevalence of primary hyperparathyroidism in a racially mixed population.
        J Clin Endocrinol Metab. 2013; 98: 1122-1129
        • Bilezikian J.P.
        • Brandi M.L.
        • Eastell R.
        • et al.
        Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop.
        J Clin Endocrinol Metab. 2014; 99: 3561-3569
        • Wilhelm S.M.
        • Wang T.S.
        • Ruan D.T.
        • et al.
        The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism.
        JAMA Surg. 2016; 151: 959-968
        • Allendorf J.
        • DiGorgi M.
        • Spanknebel K.
        • Inabnet W.
        • Chabot J.
        • Logerfo P.
        1112 consecutive bilateral neck explorations for primary hyperparathyroidism.
        World J Surg. 2007; 31: 2075-2080
        • Udelsman R.
        • Lin Z.
        • Donovan P.
        The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism.
        Ann Surg. 2011; 253: 585-591
        • Chen H.
        • Sokoll L.J.
        • Udelsman R.
        Outpatient minimally invasive parathyroidectomy: A combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay.
        Surgery. 1999; 126 (discussion 1021–1022): 1016-1021
        • Schneider D.F.
        • Mazeh H.
        • Sippel R.S.
        • Chen H.
        Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases.
        Surgery. 2012; 152: 1008-1015
        • Schneider D.F.
        • Mazeh H.
        • Chen H.
        • Sippel R.S.
        Predictors of recurrence in primary hyperparathyroidism: An analysis of 1386 cases.
        Ann Surg. 2014; 259: 563-568
        • Lou I.
        • Balentine C.
        • Clarkson S.
        • Schneider D.F.
        • Sippel R.S.
        • Chen H.
        How long should we follow patients after apparently curative parathyroidectomy?.
        Surgery. 2017; 161: 54-61
        • Mallick R.
        • Nicholson K.J.
        • Yip L.
        • Carty S.E.
        • McCoy K.L.
        Factors associated with late recurrence after parathyroidectomy for primary hyperparathyroidism.
        Surgery. 2020; 167: 160-165
        • Ryder C.Y.
        • Jarocki A.
        • McNeely M.M.
        • et al.
        Early biochemical response to parathyroidectomy for primary hyperparathyroidism and its predictive value for recurrent hypercalcemia and recurrent primary hyperparathyroidism.
        Surgery. 2021; 169: 120-125
        • Carsello C.B.
        • Yen T.W.
        • Wang T.S.
        Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: Does it matter?.
        Surgery. 2012; 152 (discussion 581–583): 575-581
        • Stewart Z.A.
        • Blackford A.
        • Somervell H.
        • et al.
        25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy.
        Surgery. 2005; 138 (discussion 1025–1026): 1018-1025
        • Denizot A.
        • Pucini M.
        • Chagnaud C.
        • Botti G.
        • Henry J.F.
        Normocalcemia with elevated parathyroid hormone levels after surgical treatment of primary hyperparathyroidism.
        Am J Surg. 2001; 182: 15-19
        • Westerdahl J.
        • Valdemarsson S.
        • Lindblom P.
        • Bergenfelz A.
        Postoperative elevated serum levels of intact parathyroid hormone after surgery for parathyroid adenoma: Sign of bone remineralization and decreased calcium absorption.
        World J Surg. 2000; 24: 1323-1329
        • Rodgers S.E.
        • Hunter G.J.
        • Hamberg L.M.
        • et al.
        Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography.
        Surgery. 2006; 140 (discussion 940–941): 932-940
        • Vu T.H.
        • Schellingerhout D.
        • Guha-Thakurta N.
        • et al.
        Solitary parathyroid adenoma localization in technetium Tc99m sestamibi SPECT and multiphase multidetector 4D CT.
        AJNR Am J Neuroradiol. 2019; 40: 142-149
        • Yeh R.
        • Tay Y.D.
        • Tabacco G.
        • et al.
        Diagnostic performance of 4D CT and sestamibi SPECT/CT in localizing parathyroid adenomas in primary hyperparathyroidism.
        Radiology. 2019; 291: 469-476
        • Broome D.T.
        • Naples R.
        • Bailey R.
        • et al.
        Use of preoperative imaging in primary hyperparathyroidism.
        J Clin Endocrinol Metab. 2021; 106: e328-e337
        • Alobuia W.
        • Annes J.
        • Kebebew E.
        Genetic testing in endocrine surgery: Opportunities for precision surgery.
        Surgery. 2020; 168: 328-334